Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma

Hiroki Honda1, Masaaki Takamura1, Satoshi Yamagiwa1, Takuya Genda2, Ryoko Horigome1, Naruhiro Kimura1, Toru Setsu1, Kentaro Tominaga1, Hiroteru Kamimura1, Yasunobu Matsuda1, Toshifumi Wakai3, Yutaka Aoyagi1 & Shuji Terai1

Cell motility plays an important role in intrahepatic metastasis of hepatocellular carcinoma (HCC), and predicts poor prognosis in patients. The present study investigated the role of a disintegrin and metalloproteinases (ADAMs) in HCC, since these proteins are known to be associated with cell motility. We confirmed the expression of 12 ADAMs with putative metalloproteinase activity in HCC cells, and established a KYN-2 HCC cell line stably expressing short interfering RNA against ADAM21 to investigate the effect of ADAM21 deficiency on HCC cell motility and metastasis in vitro and in vivo. We also examined ADAM21 expression in a cohort of 119 HCC patients by immunohistochemistry. ADAM21 was overexpressed in KYN-2 cells, and its knockdown reduced invasion, migration, proliferation, and metastasis relative to controls. In clinical specimens, ADAM21 positivity was associated with vascular invasion, large tumor size, high histological grade, and lower overall and recurrence-free survival as compared to cases that were negative for ADAM21 expression. A multivariate analysis revealed that ADAM21 positivity was an independent risk factor for overall (P = 0.003) and recurrence-free (P = 0.003) survival. These results suggest that ADAM21 plays a role in HCC metastasis and can serve as a prognostic marker for disease progression.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, with approximately 700,000 deaths worldwide and more than 30,000 in Japan each year1,2. Most HCC patients have poor prognosis due to the high incidence of intrahepatic metastasis and recurrence after curative therapeutic intervention3. The former results from the dispersal of cells around the tumor periphery to surrounding liver tissues through the portal vein4,5, although the underlying mechanisms are not well understood. We previously reported that HCC cell lines with high motility exhibit high rates of intrahepatic metastasis in vivo6. Inhibiting motility in highly metastatic HCC cell lines by overexpressing a dominant-negative Rho kinase or by treatment with Rho kinase inhibitor decreased metastatic potential, indicating that cell motility plays an important role in intrahepatic metastasis of HCC6,7.

A disintegrin and metalloproteinases (ADAMs) were originally discovered as a family of proteins with sequence similarity to the reprolysin family of snake venomases8. To date, 21 members of the human ADAM family have been identified9. ADAMs share an N-terminal secretory signal sequence, prodomain, and metalloprotease-like, disintegrin-like, cysteine-rich, epidermal growth factor-like, transmembrane, and cytoplasmic domains10. More than half of ADAMs have an active site in the metalloprotease domain with a common HEXXHXXGXXH sequence, similar to matrix metalloproteinases11. Protease-type ADAMs are closely associated with cell invasion, proliferation and metastasis. Upregulation of ADAM17 is a pathological feature of HCC12; suppression of

1Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 2Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka, Japan. 3Division of Digestive and General Surgery Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Correspondence and requests for materials should be addressed to M.T. (email: atmci@med.niigata-u.ac.jp)
ADAM17 by the microRNA miR-122 inhibited in vitro migration, invasion, in vivo tumorigenesis, intrahepatic metastasis, and local invasion in the livers of nude mice13. However, there have been no systematic studies on the role of other protease-type ADAMs in HCC.

To address this issue, the present study analyzed the expression of 12 protease-type ADAMs in HCC cell lines and found that ADAM21 was overexpressed in the highly motile and metastatic KYN-2 HCC cell line. We also found that high ADAM21 expression predicted poor prognosis in HCC patients. These results provide the first evidence that ADAM21 plays an important role in the malignant progression of HCC.

Results
Real-time quantitative PCR analysis of proteinase-type ADAM expression in HCC cell lines. We evaluated the mRNA levels of ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, and 33—which have putative metalloproteinase activity—in KYN-2, PLC/PRF/5, and HepG2 cells and normal liver tissue by real-time PCR. ADAM17, 19, and 21 were more highly expressed in KYN-2 cells than in PLC/PRF/5 and HepG2 cells and normal liver (Fig. 1A). ADAM17 and 19 expression has been linked to many human cancers9, and ADAM17 is a target of the micro (mi)RNA miR-122 and is involved in HCC tumorigenesis and metastasis13. Many studies have reported that ADAM19 is a direct target of several miRNAs, including miR-153, -30c, or -145 and plays an important role in cell migration, invasion, and proliferation in various cancers14–16. Moreover, dysregulation of transforming growth factor-β/SMAD4 signaling leads to epigenetic silencing of its downstream target ADAM19 in ovarian cancer cells17. Therefore, in this study, we evaluated the expression and function of ADAM21 in HCC tumorigenesis and metastasis. An immunoblot analysis revealed that ADAM21 protein was highly expressed in KYN-2 cells and expressed at low levels in HepG2 cells and normal liver (Fig. 1B).

ADAM21 knockdown inhibits HCC cell proliferation, migration, and invasion and induces cell-cycle arrest and apoptosis. To investigate the in vitro function of ADAM21, KYN-2 cells were stably transfected with either a control short interfering (si) RNA or one targeting ADAM21 (Fig. 2A). Similar to the parent cell line, cells expressing control siRNA had a ruffled membrane and fusiform shape without cell-to-cell contacts (Fig. 2B). In contrast, cell expressing the siRNA against ADAM21 had fewer membrane ruffles and formed relatively cohesive colonies (Fig. 2B). We investigated changes in the expression of epithelial–mesenchymal transition (EMT) markers such as E-cadherin, zona occludens (ZO)-1, N-cadherin, and vimentin by immunoblotting upon ADAM21 knockdown and found no changes in E-cadherin and ZO-1 levels, whereas N-cadherin and vimentin were not detected in KYN-2 cells expressing either control or ADAM21 siRNA (data not shown). The cell proliferation assay revealed that ADAM21 knockdown reduced the growth of KYN-2 cells (P < 0.05 at 48 and 72h and P < 0.01 at 96h vs. control siRNA-transfected cells) (Fig. 2C, upper panel). We performed a cell-cycle analysis to clarify the mechanism by which ADAM21 knockdown inhibits cell proliferation and found that 96h after seeding, KYN-2 cells expressing ADAM21 siRNA were arrested in G0/G1, and a smaller proportion were in S phase compared to KYN-2 cells expressing control siRNA (P < 0.01 and P = 0.01, respectively) (Fig. 2C, middle panel). Immunoblot analysis revealed detectable cleavage of poly (adenosine

Figure 1. Expression of proteinase-type ADAMS in KYN-2, PLC/PRF/5, and HepG2 cells and normal liver tissue. (A) Relative mRNA levels of 12 ADAMS were analyzed by real-time PCR. Values were normalized to the level of β-actin in each sample. Experiments were performed three times. Data represent means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test). (B) Immunoblot analysis of ADAM21 protein levels in HCC cell lines and human liver tissue lysate. β-actin served as a loading control.
disphosphate)-ribose polymerase (PARP) (Fig. 2C, lower panel). In addition, migration and invasion assays revealed that ADAM21 siRNA-expressing KYN-2 cells showed significantly reduced migration (P < 0.001) and invasion (P < 0.01) (Fig. 2D). We also observed a similar effect in cells transfected with siRNA oligonucleotides (Supplemental Fig. 1A–C).

**ADAM21 knockdown slows tumor growth in a murine orthotopic implantation model.** To determine whether ADAM21 is involved in tumorigenesis or intrahepatic metastasis in vivo, KYN-2 cells expressing siRNA against ADAM21 or control siRNA were orthotopically implanted into the livers of SCID mice. Tumors formed in all mice at the site of injection; however, the maximum diameter of the primary tumor was smaller in the ADAM21 siRNA group than in the control siRNA group (Fig. 3A); this corresponded to a lower incidence of intrahepatic metastasis in the former (Fig. 3B), although the difference was not statistically significant. These results indicate that ADAM21 knockdown may inhibit tumorigenesis and intrahepatic metastasis in vivo.

**High ADAM21 expression in HCC tumors is associated with clinicopathological parameters of HCC.** We examined ADAM21 protein expression in 119 patients with HCC by immunohistochemistry. ADAM21 protein was detected in the cytoplasm of tumor cells and exhibited various staining patterns (Fig. 4A). A total of 25/119 cases (21.0%) were positive for ADAM21 (high expression), whereas 94/119 (79.0%) were negative (unchanged expression, loss, or both negative expression). Table 1 summarizes the relationship between the degree of ADAM21 expression and various clinicopathological parameters; positive ADAM21 expression was related to large tumor size (P = 0.004), high histological grade (P = 0.014), and vascular invasion (P = 0.005).

**ADAM21 positivity is associated with poor overall survival (OS) after resection.** A univariate analysis revealed that serum α-fetoprotein (AFP) level (P = 0.001), number of hepatic tumors (P = 0.009), vascular invasion (P = 0.010), and ADAM21 expression (P = 0.001) (Fig. 4B) were significant prognostic factors for
overall survival (OS) (Table 2). Variables that were significant in the univariate analyses were subjected to multivariate analyses, which revealed that serum AFP levels $\geq 20$ ng/mL ($P = 0.009; \text{hazard ratio } [\text{HR}] = 2.398, 95\% \text{ confidence interval } [\text{CI}]: 1.250–4.601$), multiple hepatic tumors ($P = 0.036; \text{HR} = 1.932, 95\% \text{CI}: 1.044–3.573$), and ADAM21 positivity ($P = 0.003; \text{HR} = 2.778, 95\% \text{CI}: 1.414–5.458$) were independent prognostic factors for unfavorable OS (Table 2).

ADAM21 positivity is associated with poor recurrence-free survival (RFS) after resection. A univariate analysis revealed that cirrhosis ($P = 0.026$), serum AFP levels ($P = 0.003$), number of hepatic tumors ($P < 0.001$), and ADAM21 positivity ($P < 0.001$) (Fig. 4C) were prognostic factors for recurrence-free survival (RFS) (Table 3). Multivariate analyses indicated that serum AFP levels $\geq 20$ ng/mL ($P = 0.007; \text{HR} = 1.854, 95\% \text{CI}: 1.183–2.904$), multiple hepatic tumors ($P = 0.002; \text{HR} = 2.034, 95\% \text{CI}: 1.293–3.200$), and ADAM21 positivity ($P = 0.001; \text{HR} = 2.473, 95\% \text{CI}: 1.454–4.205$) were independent prognostic factors for unfavorable RFS (Table 3).

Discussion
Recent advances in both diagnosis and therapeutics have allowed clinicians to identify HCC at earlier stages and recommend treatment in a timely manner. However, the prognosis of HCC remains poor, largely due to the high incidence of intrahepatic metastasis and recurrence after curative therapeutic intervention. Additionally, although recent progress has advanced our knowledge and understanding of the molecular pathogenesis of HCC and the signaling pathways involved, the only mechanism-based pharmaceutical currently available is sorafenib. There is therefore a need to identify biomarkers for predicting HCC recurrence and prognosis as well as new therapeutic targets.

We previously demonstrated that cell motility plays a critical role in intrahepatic metastasis of HCC. In the present study, we examined protease-type ADAMs that are known to facilitate cell migration and invasion via proteolytic cleavage of extracellular matrix components, and found that ADAM21 was selectively overexpressed in KYN-2 cells. ADAM21 (also known as ADAM31) was first identified as a human testis-specific membrane metalloprotease with similarity to ADAM1 (fertilin- α), suggesting a role in sperm function.
and adult rodent central nervous system, ADAM21 is thought to be involved in axonal outgrowth and/or synapse formation\(^1\). There has been only one study on ADAM21 that identified this protein as a candidate factor involved in the invasion of HT29 colon cancer cells \textit{in vitro}\(^2\). Our findings support this earlier report and provide further evidence that silencing ADAM21 in KYN-2 cells causes cell-cycle arrest and inhibits cell proliferation, migration, invasion, and metastasis \textit{in vitro} and \textit{in vivo}. Although ADAM21 knockdown resulted in morphological changes to an epithelial phenotype, there were no changes in EMT marker expression, suggesting that ADAM21 knockdown alone may not be sufficient to reverse EMT. Recently, two definitive \textit{in vivo} studies demonstrated that EMT is not relevant to metastasis but is associated with chemoresistance in breast and pancreatic cancers\(^22,23\). Further study is needed to determine whether this applies to intrahepatic metastasis of HCC. In our animal model, ADAM21 knockdown did not completely abolish intrahepatic metastasis, indicating that it is a complex process mediated by many factors\(^24\).

Our analysis of tissue samples from HCC patients undergoing curative resection showed that ADAM21 expression varied, and was present not only in tumor cells but also in adjacent non-neoplastic hepatocytes. It has been reported that many types of tumor produce growth factors that stimulate the proliferation and invasion of tumor cells themselves (in an autocrine fashion) and of surrounding normal cells (in a paracrine fashion)\(^25\). To our knowledge, there are no previous reports on the regulatory mechanism of ADAM21. One possible mechanism is the paracrine stimulation of adjacent non-neoplastic hepatocytes by unidentified factors that upregulate ADAM21 production by tumor cells.

Our clinicopathological study showed that high ADAM21 expression level in HCC tumors is closely related to large tumor size, high histological grade, and presence of vascular invasion and is an independent risk factor for poor OS and RFS. This is consistent with the results of our \textit{in vitro} and \textit{in vivo} studies and suggests that ADAM21 is a potential biomarker for HCC progression. However, further studies are needed in order to identify the physiological substrate(s) of ADAM21 and clarify its mechanism of action in HCC.

In conclusion, ADAM21-mediated cell motility plays an important role in HCC metastasis and is a prognostic biomarker for HCC patient OS and RFS after hepatectomy. These results indicate that therapeutic strategies targeting ADAM21 may be an effective treatment for preventing HCC metastasis and recurrence.

**Materials and Methods**

**Cell lines and culture.** The PLC/PRF/5 cell line was obtained from the Japanese Collection of Research Bioresources (Osaka, Japan); HepG2 cells were obtained from the RIKEN BioResource Center (Tsukuba, Japan); and the KYN-2 cell line was provided by Dr. H. Yano (Kurume University, Kurume, Japan)\(^26\). We previously

---

**Figure 4.** Immunohistochemical analysis of ADAM21 expression in 119 HCC tissue specimens and Kaplan-Meier survival curves for OS and RFS according to ADAM21 expression. (A) Representative images of HCC tissue specimens with various ADAM21 staining patterns (high expression, unchanged expression, loss of expression, or both negative expression). The final results were classified as ADAM21-positive (high expression) or ADAM21-negative (unchanged expression, loss expression, or both negative expression). Original magnification: 200×. (B-C) Post-resection survival (B) and RFS (C) were worse in ADAM21-positive patients (blue line) than in the ADAM21-negative group (red line; log-rank test, P = 0.001 and P < 0.001, respectively). The number of patients at risk reflects those remaining in the group at the indicated time point.
characterized KYN-2 cells as a highly motile and metastatic HCC cell line, whereas PLC/PRF/5 and HepG2 cells exhibit low motility and metastatic potential. All cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 \( \mu \)g/ml streptomycin at 37 °C in a humidified atmosphere of 5% CO₂. When required, the medium was supplemented with 0.25 \( \mu \)g/mL puromycin (Invitrogen, Carlsbad, CA, USA).

**Real-time PCR analysis.** Total RNA was isolated using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. cDNA was synthesized from 1 \( \mu \)g of total RNA using a PrimeScript RT reagent kit (Takara Bio, Otsu, Japan) and used as a template for real-time PCR on a Light Cycler System (Roche Diagnostics, Indianapolis, IN, USA). Primer/probe sets were selected from the Taqman Gene Expression Assays collection (Applied Biosystems, Foster City, CA) (Table 4). PCR conditions were as follows: 95 °C for 10 min, and 45 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 1 s. Results were normalized to the levels of human \( \beta \)-actin mRNA. Measurements were performed in triplicate.

**Antibodies.** A mouse monoclonal anti-ADAM21 antibody was produced by MBL Co. (Nagoya, Japan) using a peptide corresponding to amino acids 710–722 as antigen. The antibody was used for immunoblotting (diluted 1:1000) and immunohistochemistry (diluted 1:100). A rabbit monoclonal anti-cleaved PARP (Asp214) antibody (Cell Signaling Technology, Beverly, MA) was used for immunoblotting (diluted 1:1000). A mouse monoclonal anti-\( \beta \)-actin antibody (clone AC-15; Sigma-Aldrich, St. Louis, MO) was used as a loading control for immunoblotting (diluted 1:5000).

**Immunoblotting.** Cell lysates were prepared and immunoblotting was carried out as previously described. Briefly, 30 \( \mu \)g of protein were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to an Immobilon membrane (Millipore, Bedford, MA, USA) that was blocked and probed with primary antibodies followed by the horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare, Piscataway, NJ, USA). Peroxidase-labeled bands were visualized with enhanced chemiluminescence detection reagents (GE Healthcare) according to the manufacturer’s instructions. To confirm equal loading, the membrane was reprobed with anti-\( \beta \)-actin antibody.

**SiRNA-mediated knockdown of ADAM21.** SiRNA against ADAM21 and control siRNA were generated using the pGENE vector (Nagase, Tokyo, Japan) and the following target sequences: ADAM21, GTAGAAACATTAGTACATC and control (T7STOP), CACCTTTTTTT. The siRNAs or control plasmid were transfected into KYN-2 cells with Lipofectamine 2000 (Invitrogen), and stable cell lines were generated from puromycin-resistant colonies.

### Table 1. Relationship between clinicopathologic parameters and ADAM21 expression in patients with hepatocellular carcinoma.

| Variable                        | Total (n = 119) | Positive (n = 25) | Negative (n = 94) | P value |
|---------------------------------|----------------|------------------|------------------|---------|
| Age (years)                     | 70 (35–81)     | 71 (51–80)       | 70 (35–81)       | 0.396   |
| Gender                          |                |                  |                  |         |
| Male                            | 85             | 17               | 68               | 0.804   |
| Female                          | 34             | 8                | 26               |         |
| Cirrhosis                       |                |                  |                  |         |
| Absent                          | 55             | 14               | 41               | 0.367   |
| Present                         | 64             | 11               | 53               |         |
| Serum AFP levels (ng/ml)        |                |                  |                  |         |
| \( \geq 20 \)                   | 56             | 14               | 42               | 0.371   |
| \( < 20 \)                      | 63             | 11               | 52               |         |
| Tumor size (cm)                 | 3.1 (1.0–16.0) | 3.8 (2.0–16.0)   | 3.0 (1.0–13.0)   | 0.004   |
| Tumor multiplicity              |                |                  |                  |         |
| Solitary                        | 73             | 14               | 59               | 0.645   |
| Multiple                        | 46             | 11               | 35               |         |
| Histological grade              |                |                  |                  |         |
| Well                            | 26             | 1                | 25               | 0.014   |
| Moderate/Poor                   | 93             | 24               | 69               |         |
| Vascular invasion               |                |                  |                  |         |
| Absent                          | 93             | 14               | 79               | 0.005   |
| Present                         | 26             | 11               | 15               |         |
| pTNM stage                      |                |                  |                  |         |
| I+II                            | 104            | 19               | 85               | 0.084   |
| III                             | 15             | 6                | 9                |         |
Cell proliferation assay. Cells (1.0 × 10^3) resuspended in medium were seeded in a 96-well plate. Viable cells were quantified every 24 h with Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s protocol. Data represent mean ± SD of five independent experiments.
Cell cycle analysis. Cell cycling was analyzed with the cell-clock assay (Biocolor, Carrickfergus, UK) according to the manufacturer’s protocol. Cell-clock dye is a redox dye that is readily taken up by live cells. In G0/G1, S, or G2/M phase, the dye is yellow, green, or dark blue in color, respectively. Cells in different cell cycle phases can be visualized from micrographs acquired in the bright field channel. The different fractions were quantified using ImageJ v.1.60 software (National Institutes of Health, Bethesda, MD, USA).

Cell migration assay. Cell migration was evaluated with the transwell chamber assay (24-well-format with 8 μm pores; BD Biosciences, Bedford, MA, USA). Cells resuspended in RPMI 1640 medium containing 0.5% FBS were added to the upper chamber (5 × 10^4 cells/well), and the lower chamber was filled with medium containing 10% FBS as a chemoattractant. After incubation for 24 h at 37 °C and 5% CO_2, the membranes were fixed and stained with Diff-Quick solution (Sysmex International Reagents, Kobe, Japan). Cells that had migrated through the pores were counted under a light microscope. Samples were prepared in triplicate and the assay was repeated three times.

Cell invasion assay. Cell invasion was assessed using BioCoat Matrigel Invasion Chambers (BD Biosciences) according to the manufacturer’s protocol. Cells resuspended in RPMI 1640 medium containing 0.5% FBS were added to the upper chamber (5 × 10^4 cells/well), and the lower chamber was filled with medium containing 20% FBS as a chemoattractant. After incubation for 30 h at 37 °C and 5% CO_2, the membranes were fixed and stained with Diff-Quick solution. Cells that had invaded through the pores were counted under a light microscope. Samples were prepared in triplicate and the assay was repeated three times.

Orthotopic implantation in mice. Male homozygous C.B-17 SCID/SCID mice were purchased from CLEA Japan (Tokyo, Japan) and maintained at the Animal Center of Niigata University School of Medicine under specific pathogen-free conditions. In vivo experiments were carried out in full compliance with regulations and were approved by the Institutional Animal Care and Committee at the Niigata University (Niigata, Japan). Six-week-old mice were used for experiments. Orthotopic implantation of KYN-2 cells and KYN-2 transfectants was performed as previously described, with slight modification. Briefly, cells were resuspended in phosphate-buffered saline containing 1% cold liquid Matrigel (Dow Corning, Corning, NY, USA; cat. no. 356230) at 1 × 10^6 cells/ml and 20 μl of the cell suspension (2 × 10^6 cells) were injected into the liver subserosa of anesthetized mice. Mice were sacrificed 4 weeks later and the livers were dissected, fixed in 10% formalin, and embedded in paraffin. To evaluate the frequency of intrahepatic metastasis, serial sections of liver tissue were stained with hematoxylin-eosin. Intrahepatic metastatic lesions were defined as either: (a) lesions in lobes other than the injected lobe; or (b) lesions that were clearly separate from the primary tumor.

Patient population. A total of 119 consecutive patients with HCC underwent initial surgical resection with curative intent at Niigata University Medical and Dental Hospital from January 2001 to December 2008. There were 85 men and 34 women and the median age was 70 years (range: 35–81 years). None of the patients received preoperative chemo- or radiotherapy. Clinicopathologic factors were established according to general guidelines for primary liver cancer as defined by the Liver Cancer Study Group in Japan and the American Joint Committee on Cancer/International Union Against Cancer Tumor-Node-Metastasis (TNM) staging system. Patients were divided into three groups according to TNM stage (I, II, and III); stage IV patients were excluded, as resection would most likely be non-curative. Written informed consent for the use of resected tissue samples was obtained from all patients in accordance with Declaration of Helsinki, and the study protocol was approved by the Human Ethics Review Committee of Niigata University Graduate School of Medical and Dental Sciences. All experiments were carried out in accordance with approved guidelines of Niigata University Graduate School of Medical and Dental Sciences.

| Genes    | Assay IDs               |
|----------|-------------------------|
| ADAM8    | Hs00923280_m1          |
| ADAM9    | Hs00177638_m1          |
| ADAM10   | Hs00153853_m1          |
| ADAM12   | Hs01106104_m1          |
| ADAM15   | Hs00984794_m1          |
| ADAM17   | Hs00234221_m1          |
| ADAM19   | Hs00224960_m1          |
| ADAM20   | Hs01083178_s1          |
| ADAM21   | Hs01652548_s1          |
| ADAM28   | Hs00248020_m1          |
| ADAM30   | Hs00253969_s1          |
| ADAM33   | Hs00905552_m1          |
| β-actin  | Hs99999903_m1          |

Table 4. Genes and respective assay IDs for the predesigned TaqMan primer and probe sets.
Patient follow-up after resection. Serum concentrations of AFP were measured, and abdominal ultrasonography and/or contrast-enhanced computed tomodgraphy was performed approximately 1 month after resection in all patients. Thereafter, patients were followed up every 3 months in outpatient clinics and monitored for disease recurrence by measuring serum AFP concentrations and/or by imaging. Patients were followed up until December 2014 with a median observation time of 63 months. At the time of disease status assessment, 42 patients had died from tumor recurrence and five had died of other causes with no evidence of disease; of the remaining patients, 38 were alive with recurrent disease and 34 were alive with no evidence of disease.

Immunohistochemistry. Sections (5 μm thick) of formalin-fixed, paraffin-embedded tissue were deparaffinized in xylene and rehydrated in ethanol, treated with 0.3% hydrogen peroxide in methanol, and immersed in citrate buffer (10 mmol/L, pH 6.0). After autoclaving (121 °C, 10 min) and preincubating with normal swine serum, the sections were incubated overnight at 4 °C with primary antibody, which was detected with the Mouse/HRP Envision + system (Dako, Carpinteria, CA, USA). Immunoreactivity was visualized using 0.05% diaminobenzidine tetrahydrochloride solution containing 0.01% hydrogen peroxide. Sections were counterstained with hematoxylin. Leydig cells in the testis tissue served as a positive control for ADAM21; negative controls were prepared by substituting normal mouse serum for primary antibody and showed no detectable labeling.

ADAM21 expression in tumor specimens was evaluated by comparison with adjacent non-neoplastic hepatocytes and was classified as high expression, unchanged expression, or loss (i.e., signal intensity of the tumor specimen was higher than, similar to, or lower than that of non-neoplastic hepatocytes, respectively) or both negative expression (i.e., the tumor specimen and non-neoplastic hepatocytes both showed no signal). However, the final results were recorded only as negative (unchanged expression, loss, or both negative expression) or positive (high expression). Hematoxylin and eosin staining and immunohistochemical analyses were carried out by two independent observers (H.H. and N.K.) who were blinded to patients’ clinicopathologic information.

Statistical analysis. Continuous variables are expressed as means ± standard deviation or median (range). Associations among variables were evaluated with the Student’s t test, Mann-Whitney U test, χ² test, or Fisher’s exact test as appropriate. Medical records and survival data were obtained for all patients. Deaths from other causes were treated as uncensored cases. The Kaplan-Meier method was used to estimate the cumulative incidences of events, and differences in these incidences were analyzed with the log-rank test. Univariate and backward stepwise multivariate survival analyses were performed using the Cox proportional hazards model. Statistical analyses were performed using SPSS v.17.0 for Windows (SPSS Inc., Chicago, IL, USA). All tests were two-sided, and P values < 0.05 were considered statistically significant.

References

1. Torre, L. A. et al. Global cancer statistics, 2012. C.A. Cancer J. Clin. 65, 87–108 (2015).
2. Umemura, T. Epidemiology of hepatocellular carcinoma in Japan. J. Gastroenterol. 44, 102–107 (2009).
3. Marquardt, J. U. & Thorgeirsson, S. S. SnapShot: Hepatocellular carcinoma. Cancer Cell. 25, 550.e1 (2014).
4. Nakashima T. Vascular changes and hemodynamics in hepatocellular carcinoma (eds Okuda, K. & Peter, R. L.) 169–203 (Wiley, 1976).
5. Kanai, T. et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer. 60, 810–819 (1987).
6. Genda, T. et al. Cell motility meditated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 30, 1027–1036 (1999).
7. Takamura, M. et al. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology. 33, 577–581 (2001).
8. McLane, M. A., Marcinkiewicz, C., Vijay-Kumar, S., Wierzbicka-Patynowski, I. & Niewiarowski, S. Viper venom disintegrins and related molecules. Proc. Soc. Exp. Biol. Med. 219, 109–119 (1998).
9. Mochizuki, S. & Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 98, 621–628 (2007).
10. Schindofor, J. & Blobel, C. P. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Biol. 112, 3603–3612 (1996).
11. Black, R. A. & White, J. M. ADAMs: focus on the protease domain. J. Cell Sci. 113, 6089–6100 (1998).
12. Ding, X., Yang, L. Y., Huang, G. W., Wang, W. & Lu, W. Q. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J. Gastroenterol. 10, 2735–2739 (2004).
13. Tsai, W. C. et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 49, 1571–1582 (2009).
14. Shan, N. et al. MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19. Biochem. Biophys. Res. Commun. 456, 385–391 (2015).
15. Zhang, Q. et al. Role of microRNA-30c targeting ADAM19 in colorectal cancer. PLoS One. 10, e0120698 (2015).
16. Sun, Z. et al. MiR-145 suppressed human retinoblastoma cell proliferation and invasion by targeting ADAM19. Int. J. Clin. Exp. Pathol. 8, 14521–14527 (2015).
17. Chan, M. W. et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia. 10, 908–919 (2008).
18. Löffler, J. et al. Soralenf in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
19. van Huijsduijnen, R. H. ADAM 20 and 21; two novel human testis-specific membrane metalloproteases with similarity to fertilin-alpha. Gene. 206, 273–282 (1998).
20. Yang, P., Baker, K. A. & Hagg, T. A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS. J. Comp. Neurol. 490, 163–179 (2005).
21. Iry, R. B. et al. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Res. 65, 1814–1821 (2005).
22. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527, 472–476 (2015).
23. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527, 525–530 (2015).
24. Talmadge, J. E. & Fidler, I. J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 70, 5649–5669 (2010).
25. Spoon, M. B. & Todaro, G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303, 878–880 (1980).
26. Yano, H. et al. A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol. Jpn. 38, 953–966 (1988).
27. Takamura, M. et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 94, 425–430 (2003).
28. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd English edn. 47–56 (Kanehara & Co., 2010).
29. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. (eds). TNM Classification of Malignant Tumours, 7th edn. (Wiley-Liss, 2009).

Acknowledgements
This work was supported by a Grant-in-Aid for Scientific Research (B) (no. 26293175) from the Ministry of Education, Science, Technology, Sports, and Culture of Japan and by the Highway Program for Realization of Regenerative Medicine from Japan Agency for Medical Research and Development. The authors thank Nomoto M and Tsuchida T in the Division of Gastroenterology and Hepatology at the Niigata University Graduate School of Medical and Dental Sciences for their excellent assistance in histological analyses.

Author Contributions
M.T., S.Y. and T.G. designed the study; H.H., M.T., R.H., T.S., K.T. and H.K. performed the in vitro and in vivo experiments; H.H., N.K., T.S., K.T. and H.K. collected the tissue samples; H.H. and N.K. performed immunohistochemistry and analyzed the data; M.T., S.Y. and Y.M. collected clinical data and contributed to the evaluation of immunohistochemistry data; M.T. drafted the manuscript and T.W., Y.A. and S.T. supervised the study. All authors read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15800-z.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017